Immunoprecise Antibodies Ltd (IPA)

NASDAQ
Currency in USD
Disclaimer
1.850
-0.010(-0.54%)
Closed
Day's Range
1.7801.880
52 wk Range
1.7005.900
Prev. Close
1.86
Open
1.83
Day's Range
1.78-1.88
52 wk Range
1.7-5.9
Volume
23,103
Average Vol. (3m)
45,238
1-Year Change
-52.56%
Shares Outstanding
25,050,260
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Daily
Weekly
Monthly
More

People Also Watch

3.0000
PFIE
+4.17%
1.000
SANW
+13.64%
3.480
OCUP
-7.94%
0.620
ORGS
0.00%
8.230
INOD
-1.91%
  • IPA Announces CFO Transition
    • ByInvesting.com
  • IPA Announces Board Refreshment
    • ByInvesting.com
  • IPA Responds to 13D Filing by Ingalls & Snyder
    • ByInvesting.com

Immunoprecise Antibodies Ltd Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.

Income Statement